<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242667</url>
  </required_header>
  <id_info>
    <org_study_id>833373</org_study_id>
    <nct_id>NCT04242667</nct_id>
  </id_info>
  <brief_title>Penn Biobank Return of Research Results Program</brief_title>
  <official_title>A Randomized Protocol Evaluating Return of Actionable Genetic Research Results to Biobank Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of the proposed research is to assess the feasibility of a randomized study
      evaluating the non-inferiority of an electronic Health (e-Health) delivery alternative (e.g.
      private web portal) as compared to return of actionable genetic research results with a
      genetic counselor.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of surveys</measure>
    <time_frame>Baseline survey prior to disclosure of results, and then two post-disclosure surveys at 2-7 days and 6 months</time_frame>
    <description>Participant will self-complete surveys to collect psychological and knowledge outcomes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hereditary Cancer</condition>
  <condition>Hereditary Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Actionable gene result for cancer risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Actionable gene result for cardiovascular disease risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>e-Health (web-based) disclosure portal</intervention_name>
    <description>Patient uses secure web-based portal to access genetic research results</description>
    <arm_group_label>Actionable gene result for cancer risk</arm_group_label>
    <arm_group_label>Actionable gene result for cardiovascular disease risk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Provider mediated disclosure</intervention_name>
    <description>Patient has disclosure of genetic research result by a provider (genetic counselor)</description>
    <arm_group_label>Actionable gene result for cancer risk</arm_group_label>
    <arm_group_label>Actionable gene result for cardiovascular disease risk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consented participant in University of Pennsylvania Biobank who previously submitted a
             DNA sample for research testing

          2. English speaking

          3. Aged 18 years or older

          4. Agreed to be re-contacted in the future or did not indicate a preference on future
             contact regarding research results

          5. Have an actionable mutation or have been selected as a control participant

          6. Have not previously received actionable results of clinical genetic testing

        Exclusion Criteria:

          1. Deceased assessed by electronic medical record, death index or identified after
             contact

          2. Evidence in the electronic medical record that the subject has already received the
             same actionable result through clinical genetic testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Bradbury, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

